Ketamine’s Mechanism of Rapid Antidepressant Activity: Evidence Gleaned from Clinical Studies (Q58213893)

https://api.crossref.org/works/10.1007%2F978-3-319-42925-0_7

Ketamine for depression: where do we go from here?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42925-0_7

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42925-0_7

Rapid antidepressant effect of ketamine in the electroconvulsive therapy setting

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42925-0_7

Ketamine as a promising prototype for a new generation of rapid-acting antidepressants

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42925-0_7

Hippocampal volume and the rapid antidepressant effect of ketamine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42925-0_7

Ketamine and rapid-acting antidepressants: a window into a new neurobiology for mood disorder therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42925-0_7

Attenuation of the neuropsychiatric effects of ketamine with lamotrigine: support for hyperglutamatergic effects of N-methyl-D-aspartate receptor antagonists.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42925-0_7

NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42925-0_7

Improvement in suicidal ideation after ketamine infusion: relationship to reductions in depression and anxiety.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42925-0_7

The role of cognitive impairment in general functioning in major depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42925-0_7

A role for inflammatory metabolites as modulators of the glutamate N-methyl-D-aspartate receptor in depression and suicidality.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42925-0_7

Control of synaptic strength by glial TNFalpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42925-0_7

Antidepressant effects of ketamine in depressed patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42925-0_7

The mood-improving actions of antidepressants do not depend on neurogenesis but are associated with neuronal remodeling.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42925-0_7

Stress-induced anhedonia is associated with hypertrophy of medium spiny neurons of the nucleus accumbens.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42925-0_7

On the safety and benefits of repeated intravenous injections of ketamine for depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42925-0_7

Cognitive impairment in euthymic major depressive disorder: a meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42925-0_7

Norepinephrine in depressive reactions. A review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42925-0_7

Ketamine as the prototype glutamatergic antidepressant: pharmacodynamic actions, and a systematic review and meta-analysis of efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42925-0_7

Acute antidepressant effects of intramuscular versus intravenous ketamine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42925-0_7

Grand challenges in global mental health

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42925-0_7

Do NMDA receptors mediate the effects of light on circadian behavior?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42925-0_7

Synaptic potentiation is critical for rapid antidepressant response to ketamine in treatment-resistant major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42925-0_7

From inflammation to sickness and depression: when the immune system subjugates the brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42925-0_7

Glutamate and the neural basis of the subjective effects of ketamine: a pharmaco-magnetic resonance imaging study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42925-0_7

Monitoring ketamine treatment response in a depressed patient via peripheral mammalian target of rapamycin activation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42925-0_7

Ketamine infusions for treatment resistant depression: a series of 28 patients treated weekly or twice weekly in an ECT clinic.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42925-0_7

A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42925-0_7

Rapid resolution of suicidal ideation after a single infusion of an N-methyl-D-aspartate antagonist in patients with treatment-resistant major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42925-0_7

A meta-analysis of cytokines in major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42925-0_7

Synaptic dysfunction in depression: potential therapeutic targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42925-0_7

A neurotrophic model for stress-related mood disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42925-0_7

Signaling pathways underlying the pathophysiology and treatment of depression: novel mechanisms for rapid-acting agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42925-0_7

Concomitant BDNF and sleep slow wave changes indicate ketamine-induced plasticity in major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42925-0_7

The BDNF val66met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42925-0_7

Connecting inflammation with glutamate agonism in suicidality.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42925-0_7

Sleep homeostasis and cortical synchronization: I. Modeling the effects of synaptic strength on sleep slow waves

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42925-0_7

Ketamine administration in depressive disorders: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42925-0_7

What did STAR*D teach us? Results from a large-scale, practical, clinical trial for patients with depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42925-0_7

Plasma brain derived neurotrophic factor (BDNF) and response to ketamine in treatment-resistant depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42925-0_7

Cognitive impairment in the remitted state of unipolar depressive disorder: a systematic review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42925-0_7

Cognitive deficits in the remitted state of unipolar depressive disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42925-0_7

The revised monoamine theory of depression: a modulatory role for monoamines, based on new findings from monoamine depletion experiments in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42925-0_7

Major Depressive Disorder in recovery and neuropsychological functioning: effects of selective serotonin reuptake inhibitor and dual inhibitor depression treatments on residual cognitive deficits in patients with Major Depressive Disorder in recover

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42925-0_7

NMDA receptor hypofunction produces opposite effects on prefrontal cortex interneurons and pyramidal neurons

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42925-0_7

Associations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42925-0_7

Rapid decrease in depressive symptoms with an N-methyl-d-aspartate antagonist in ECT-resistant major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42925-0_7

Course of improvement in depressive symptoms to a single intravenous infusion of ketamine vs add-on riluzole: results from a 4-week, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42925-0_7

Effect of baseline anxious depression on initial and sustained antidepressant response to ketamine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42925-0_7

A single infusion of ketamine improves depression scores in patients with anxious bipolar depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42925-0_7

Decreased expression of synapse-related genes and loss of synapses in major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42925-0_7

Why has it taken so long for biological psychiatry to develop clinical tests and what to do about it?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42925-0_7

The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42925-0_7

Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42925-0_7

Interactive effects of subanesthetic ketamine and subhypnotic lorazepam in humans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42925-0_7

Interactive effects of subanesthetic ketamine and haloperidol in healthy humans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42925-0_7

NMDA receptor antagonist effects, cortical glutamatergic function, and schizophrenia: toward a paradigm shift in medication development

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42925-0_7

NMDA receptor antagonism and the ethanol intoxication signal: from alcoholism risk to pharmacotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42925-0_7

Altered NMDA glutamate receptor antagonist response in recovering ethanol-dependent patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42925-0_7

Preliminary evidence of attenuation of the disruptive effects of the NMDA glutamate receptor antagonist, ketamine, on working memory by pretreatment with the group II metabotropic glutamate receptor agonist, LY354740, in healthy human subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42925-0_7

Comparative and interactive human psychopharmacologic effects of ketamine and amphetamine: implications for glutamatergic and dopaminergic model psychoses and cognitive function

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42925-0_7

Potential psychiatric applications of metabotropic glutamate receptor agonists and antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42925-0_7

Rapid-acting glutamatergic antidepressants: the path to ketamine and beyond

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42925-0_7

The change in plasma GABA, glutamine and glutamate levels in fluoxetine- or S-citalopram-treated female patients with major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42925-0_7

Brain-derived neurotrophic factor Val66Met polymorphism and antidepressant efficacy of ketamine in depressed patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42925-0_7

A randomized controlled trial of intranasal ketamine in major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42925-0_7

A preliminary naturalistic study of low-dose ketamine for depression and suicide ideation in the emergency department

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42925-0_7

mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42925-0_7

Interleukin-6 is elevated in the cerebrospinal fluid of suicide attempters and related to symptom severity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42925-0_7

Monoaminergic neurotransmission: the history of the discovery of antidepressants from 1950s until today

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42925-0_7

Family history of alcohol dependence and antidepressant response to an N-methyl-D-aspartate antagonist in bipolar depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42925-0_7

Do the dissociative side effects of ketamine mediate its antidepressant effects?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42925-0_7

Ketamine and the next generation of antidepressants with a rapid onset of action

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42925-0_7

Brain-derived neurotrophic factor and initial antidepressant response to an N-methyl-D-aspartate antagonist.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42925-0_7

The hippocampus in major depression: evidence for the convergence of the bench and bedside in psychiatric research?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42925-0_7

Targeting classical IL-6 signalling or IL-6 trans-signalling in depression?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42925-0_7

Riluzole for relapse prevention following intravenous ketamine in treatment-resistant depression: a pilot randomized, placebo-controlled continuation trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42925-0_7

Ketamine for treatment-resistant unipolar depression: current evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42925-0_7

Current status of ketamine and related compounds for depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42925-0_7

A pilot in vivo proton magnetic resonance spectroscopy study of amino acid neurotransmitter response to ketamine treatment of major depressive disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42925-0_7

Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42925-0_7

Ketamine pharmacology: an update (pharmacodynamics and molecular aspects, recent findings).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42925-0_7

Ketamine use, cognition and psychological wellbeing: a comparison of frequent, infrequent and ex-users with polydrug and non-using controls

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42925-0_7

Consequences of chronic ketamine self-administration upon neurocognitive function and psychological wellbeing: a 1-year longitudinal study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42925-0_7

Ketamine as a novel antidepressant: from synapse to behavior

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42925-0_7

Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42925-0_7

Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42925-0_7

Neurocognitive effects of ketamine and association with antidepressant response in individuals with treatment-resistant depression: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42925-0_7

Regulation of neural responses to emotion perception by ketamine in individuals with treatment-resistant major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42925-0_7

Ketamine for rapid reduction of suicidal ideation: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42925-0_7

Glutamate receptor antagonists as fast-acting therapeutic alternatives for the treatment of depression: ketamine and other compounds.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42925-0_7

The chemical nature of the main central excitatory transmitter: a critical appraisal based upon release studies and synaptic vesicle localization

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42925-0_7

REDD1 is essential for stress-induced synaptic loss and depressive behavior

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42925-0_7

Comparison of racemic ketamine and S-ketamine in treatment-resistant major depression: report of two cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42925-0_7

Single ketamine infusion and neurocognitive performance in bipolar depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42925-0_7

On the relationship between emotion and cognition

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42925-0_7

Altered NMDA glutamate receptor antagonist response in individuals with a family vulnerability to alcoholism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42925-0_7

Family history of alcohol dependence and initial antidepressant response to an N-methyl-D-aspartate antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42925-0_7

Stress, depression, and neuroplasticity: a convergence of mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42925-0_7

An innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selective N-methyl-D-aspartate antagonist, CP-101,606, in patients with treatment-refractory major depressive disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42925-0_7

Effects of intravenous ketamine on explicit and implicit measures of suicidality in treatment-resistant depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42925-0_7

Effects of ketamine on explicit and implicit suicidal cognition: a randomized controlled trial in treatment-resistant depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42925-0_7

Serial infusions of low-dose ketamine for major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42925-0_7

Ketamine: an update on the first twenty-five years of clinical experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42925-0_7

Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42925-0_7

BDNF has opposite effects on the quantal amplitude of pyramidal neuron and interneuron excitatory synapses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42925-0_7

Increased anterior cingulate cortical activity in response to fearful faces: a neurophysiological biomarker that predicts rapid antidepressant response to ketamine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42925-0_7

Anterior cingulate desynchronization and functional connectivity with the amygdala during a working memory task predict rapid antidepressant response to ketamine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42925-0_7

An investigation of amino-acid neurotransmitters as potential predictors of clinical improvement to ketamine in depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42925-0_7

From pathophysiology to novel antidepressant drugs: glial contributions to the pathology and treatment of mood disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42925-0_7

Towards a glutamate hypothesis of depression: an emerging frontier of neuropsychopharmacology for mood disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42925-0_7

Lanicemine: a low-trapping NMDA channel blocker produces sustained antidepressant efficacy with minimal psychotomimetic adverse effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42925-0_7

The catecholamine hypothesis of affective disorders: a review of supporting evidence. 1965 [classical article]

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42925-0_7

Repeated S-ketamine infusions in therapy resistant depression: a case series

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42925-0_7

Serum brain-derived neurotrophic factor, depression, and antidepressant medications: meta-analyses and implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42925-0_7

The role of inflammatory cytokines in suicidal behavior: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42925-0_7

Augmentation of response and remission to serial intravenous subanesthetic ketamine in treatment resistant depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42925-0_7

Recovery from depression, work productivity, and health care costs among primary care patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42925-0_7

Glutamate-based antidepressants: 20 years on.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42925-0_7

Immunological aspects in the neurobiology of suicide: elevated microglial density in schizophrenia and depression is associated with suicide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42925-0_7

A 12-month naturalistic observation of three patients receiving repeat intravenous ketamine infusions for their treatment-resistant depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42925-0_7

Functional antagonists at the NMDA receptor complex exhibit antidepressant actions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42925-0_7

Too many cooks? Intrinsic and synaptic homeostatic mechanisms in cortical circuit refinement

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42925-0_7

The antidepressant effect of ketamine is not associated with changes in occipital amino acid neurotransmitter content as measured by [(1)H]-MRS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42925-0_7

Meta-analysis of the BDNF Val66Met polymorphism in major depressive disorder: effects of gender and ethnicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42925-0_7

Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42925-0_7

Recovery after chronic stress fails to reverse amygdaloid neuronal hypertrophy and enhanced anxiety-like behavior.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42925-0_7

Peripheral proinflammatory markers associated with ketamine response in a preclinical model of antidepressant-resistance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42925-0_7

R-ketamine: a rapid-onset and sustained antidepressant without psychotomimetic side effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42925-0_7

Serum interleukin-6 is a predictive biomarker for ketamine's antidepressant effect in treatment-resistant patients with major depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42925-0_7

Repeated stress causes cognitive impairment by suppressing glutamate receptor expression and function in prefrontal cortex.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42925-0_7

Magnetic resonance spectroscopy studies of glutamate-related abnormalities in mood disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42925-0_7

A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42925-0_7

Replication of ketamine's antidepressant efficacy in bipolar depression: a randomized controlled add-on trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42925-0_7

Human biomarkers of rapid antidepressant effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42925-0_7

Glucocorticoids, cytokines and brain abnormalities in depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42925-0_7

Ketamine: synaptogenesis, immunomodulation and glycogen synthase kinase-3 as underlying mechanisms of its antidepressant properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42925-0_7

Cyloserine as an antidepressant agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42925-0_7

Correlation between plasma levels of glutamate, alanine and serine with severity of depression

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42925-0_7

Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42925-0_7

Neurocognitive effects of ketamine in treatment-resistant major depression: association with antidepressant response.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42925-0_7

The stressed synapse: the impact of stress and glucocorticoids on glutamate transmission

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42925-0_7